Mylin Torres named director of Glenn Family Breast Center at Winship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MYLIN TORRES was named director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University. She succeeds Ruth O’Regan, who now heads the University of Wisconsin Division of Hematology and Oncology. Torres is an associate professor in Emory’s Department of Radiation Oncology and a member of Winship’s Cancer Prevention and Control Program....

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login